An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access
NACompletedINTERVENTIONAL
Timeline
Start Date
Not specified
Conditions
Cytomegalovirus RetinitisHIV Infections
Interventions
DRUG
Ganciclovir
Trial Locations (1)
94303
Roche Global Development - Palo Alto, Palo Alto
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT00002135 - An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access | Biotech Hunter | Biotech Hunter